Novo Nordisk built an entire phase 3 program, branded CagriSema, around the idea of bolting an amylin analog onto a GLP-1 agonist
Sam Azoulay, MD, Chief Medical Officer
Comparing to what clinical trials used In the landmark STEP trials that led to Wegovy approval, participants escalated to 2.4 mg weekly
However, this study did not measure the confounding factors, and the rate of withdrawal due to adverse drug reactions was not evaluated that limit the studys clinical efficacy
I love how it has been minimally processed (because of the law some heat processing is required), all organic, no hormones, antibiotics, and year-round pasture fed